Biogen (BIIB) fundamentals: P/E, valuation, undervalued?
Biogen · Health Care · ref. ETF XLV · price $221.5
In short — Biogen trades at 39.2× earnings (P/E), 13.4× forward, with a net margin of 8.3 % and revenue growth of +3 %. Read: High P/E (P/E 39 (above average)).
Is Biogen stock cheap or undervalued? A good time to buy? Here are its fundamentals — P/E, PEG, margin and income statement — to judge its valuation.
📈 1-year price
$221.5+67.0% over range
Aug 28, 25low $132.22 · high $221.56Aug 27, 26
📏 Click 2 points (left → right) to measure the change · click again to clear.
SellBuy
Buy
68% recommend buying · 19 analysts
Valuation : High P/E — P/E 39 (above average)
Valuation
39.2
P/E (price/earnings)
13.4
Forward P/E
—
PEG
1.7
Price/book (P/B)
$32.7B
Market cap
5.65
EPS
Profitability & growth
8.3 %
Net margin
+3 %
Revenue growth
-85 %
Earnings growth
$8.4B
Total debt
Biogen income statement
| Fiscal year | Revenue | Net income | Margin |
|---|---|---|---|
| 2022 | $10.2B | $3.0B | 29.9 % |
| 2023 | $9.8B | $1.2B | 11.8 % |
| 2024 | $9.7B | $1.6B | 16.9 % |
| 2025 | $9.9B | $1.3B | 13.1 % |
⚠️ Indicative financial data (Yahoo Finance), not investment advice. Amounts in $.
Frequently asked questions
What is Biogen's P/E and is the stock undervalued? What's a good P/E?
Biogen's P/E is 39.2 (forward 13.4). Below ~15 = fairly cheap, above ~30 = expensive. Our valuation verdict: "High P/E".
Is Biogen profitable?
Biogen has a net margin of 8.3 % (EPS 5.65). The company is profitable.
Is BIIB stock expensive?
Our read: "High P/E" — P/E 39 (above average). Cross-check with growth and sector.
💬 A question about Biogen? The JPI assistant answers using our backtest data.